Programs

Closing the Gaps in NSCLC

Not only is lung cancer the leading cause of cancer deaths among females and males, but it’s also the most common type of cancer. Despite its high prevalence and mortality rates, communicative care between non-small cell lung cancer (NSCLC) patients and their providers is still unfortunately lacking.

In an effort to both address and resolve this disparity, Closing the Gaps in NSCLC will focus on the latest guidelines and the current therapeutic landscape within NSCLC.

This non-certified educational series is sponsored by Lilly. Content for this series is produced and controlled by ReachMD. This series is intended for healthcare professionals only.

Sponsored by

LikeLikedUnlike

Episodes 31-36 of 36

- Paul Doghramji, MD
  Peer
- Tony Y. Hu, PhD
  Peer
0
Closing the Gaps in NSCLC
Investigating a Potential Serum Biomarker for Lung Cancer
Investigating a Potential Serum Biomarker for Lung Cancer
- Stephen Liu, MD
  Peer
1
Closing the Gaps in NSCLC
How Immune Checkpoint Inhibitors Changed the Therapeutic Landscape for NSCLC
How Immune Checkpoint Inhibitors Changed the Therapeutic Landscape for NSCLC
- Jennifer Caudle, DO
  Peer
- Stephen Liu, MD
  Peer
2
Closing the Gaps in NSCLC
Reviewing First-Line Systemic Therapies for Metastatic Non-Small Cell Lung Cancer
Reviewing First-Line Systemic Therapies for Metastatic Non-Small Cell Lung Cancer
- John J. Russell, MD
  Peer
- Mark Sundermeyer, MD
  Peer
5
Closing the Gaps in NSCLC
The Role of Primary Care in Diagnosing NSCLC
The Role of Primary Care in Diagnosing NSCLC
- Christine Bestvina, MD
  Peer
1
Closing the Gaps in NSCLC
Tips on Treating Progressive Metastatic Non-Small Cell Lung Cancer
Tips on Treating Progressive Metastatic Non-Small Cell Lung Cancer
- Christine Bestvina, MD
  Peer
1
Closing the Gaps in NSCLC
Getting Ahead of Recurrence in NSCLC
Getting Ahead of Recurrence in NSCLC